Genovis AB (publ) announces Extraordinary General Meeting
The Board of Directors of Genovis AB (publ) has decided to convene an Extraordinary General Meeting on Friday, December 20, 2019 since Mårten Winge decided to leave the board for personal reasons. We regret that Mårten leaves the board and would like to thank him for the great effort he made for the company's success during the years he led the board's work. At the same time, we are pleased to be able to propose to the Meeting Sarah Fredriksson, Genovis founder, as new chairman.
Details of the proposals for the Meeting are set out in the notice, which is presented below. The notice will be published in Post- och Inrikes Tidningar and on the company's website within the next few days.
Genovis AB (publ) will hold an Extraordinary General Meeting on Friday, December 20, 2019 in Genovis premises at Scheeletorget 1 (The Spark) Medicon Village, Lund.
12:00 p.m. – 12:20 p.m. Registration 12:30 pm ExtraordinaryGeneral Meeting convened
Right to participate. Registration
Shareholders who are registered in the register of shareholders maintained by Euroclear Sweden AB on December 13, 2019 and who have notified the company of their intention to attend the Annual General Meeting by no later than December 16, 2019, preferably before 3:00 p.m., have the right to attend the Annual General Meeting. Notification may be made by mail at Genovis AB (publ), Box 790, S-220 07 Lund, Sweden, by phone +46 (0)46-10 12 30 or by email: info@genovis.com. Upon notification, shareholders must provide their name/company name, personal identity number/corporate identity number, address and phone number. Information about the number of assistants (maximum two) that the shareholder intends to bring to the meeting should also be included.
Shareholders who are represented by proxy shall issue a written, signed and dated power of attorney for the proxy. Shareholders should submit the power of attorney together with the notification of their intention to participate at the AGM. The expiry date of the proxy document may be no more than five years from its issue. Proxy forms are available on the company’s website, www.genovis.com. Representatives of legal entities must present a copy of the certificate of registration or equivalent authorization documents showing the authorized signatory.
Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to attend the meeting, request that their nominee re-register their shares in their own name, so that the shareholder is registered in the shareholder register on December 13, 2019. Such registration may be temporary.
Proposed Agenda
- Opening of the Meeting.
- Election of Chairman of the Meeting.
- Preparation and approval of voting list.
- Approval of the agenda.
- Election of one or two persons to verify the minutes.
- Determination of whether the Meeting was duly convened
- Dismissal and election of director and chairperson of the Board.
- Meeting adjourned.
Item 7 Dismissal and election of director and chairperson of the Board
The company’s principal owner proposes the dismissal of Mårten Winge, who is resigning from the Board of Directors at his own request. Sarah Fredriksson has been proposed to replace Mårten Winge. The company’s principal owner propose that Sarah Fredriksson be elected to chair the Board.
Sarah Fredriksson in brief
Sarah Fredriksson, MSc, PhD; born 1968
Sarah is the CEO of Aqilion AB, a Swedish life science company that starts, develops and sells pharmaceutical projects at an early phase in the drug discovery process. In addition, she is a member of the board of directors of Sweden Bio, Respiratorius AB and LU Holding AB, as well as chairperson of the board of Edvince AB.
Sarah Fredriksson is the founder of Genovis and served as CEO of the company until 2015, after which she was chairperson of the board until 2016. In 2016 she was a finalist for the EU Prize for Women Innovators for her work at Genovis.
Lund, December 2019
Genovis AB (publ)
Board of Directors
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com
ABOUT GENOVIS
Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.
The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.
This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.